CRBP ▲ +11.0% - Corbus Pharmaceuticals Holdings, Inc. $CRBP - Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity Corbus Pharmaceuticals jumped 11.0% after announcing positive topline results from its CANYON-1 trial of CRB-913, an oral daily treatment for obesity. The favorable data from the phase 2 study boosted investor confidence in the company's obesity pipeline, a competitive and high-value therapeutic area. 14-SEP-2026 07:01 AM ET